ClinicalTrials.gg
Not yet recruitingNCT06024967ESCALATEUpdated Sep 11, 2023

A Study to Investigate the Safety and Efficacy of Once-weekly PEG-somatropin (GenSci004) in Children With Growth Hormone Deficiency

A Phase 3 interventional study of PEG-somatropin in GHD, sponsored by Changchun GeneScience Pharmaceutical Co., Ltd.. Not yet recruiting. Open to participants aged 6 Months to 17 Years. Per ClinicalTrials.gov, last updated 2023-09-11.

Sponsored by Changchun GeneScience Pharmaceutical Co., Ltd. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by May 2025, 1 year 6 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
180
Allocation
Not applicable
Ages
6 Months to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 60 studies testing Human Growth Hormone in Dwarfism, Pituitary — 3 open to participants now, 3 under way, 2 of them phase 3. Human Growth Hormone · Dwarfism, Pituitary.

Planned enrollment
10th of 60
180 · median 66
Started
2023
the only one that year
Phase 3
23 of 60
2 open now
Registered
60th of 60
by date
Lead sponsor
10 of 60
Changchun GeneScience Pharmaceutical Co., Ltd.

Among the 60 studies testing Human Growth Hormone in Dwarfism, Pituitary, this one is the 10th largest by planned enrollment, is the only one that started in 2023, is one of 23 in phase 3, and was the 60th registered.

Dwarfism, Pituitary

252 studies on the registry are indexed under Dwarfism, Pituitary; 30 are open to participants now.

Browse Dwarfism, Pituitary studies →

Open to participants now

3 of the 60 studies testing Human Growth Hormone in Dwarfism, Pituitary are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About Human Growth Hormone

Human Growth Hormone: first FDA approval 1986 (HUMATROPE), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 20 Dwarfism, Pituitary studies recruiting now, 5 (25%) set no upper age limit and 12 (60%) stop at 75 or younger; 11 take children under 18; 4 take healthy volunteers.

This study: 6 Months to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 60 studies testing Human Growth Hormone in Dwarfism, Pituitary, or all of them as a file.
02

Study summary

The purpose of this Phase 3 study is to evaluate the safety and efficacy of once-weekly GenSci004 over 108 weeks in children with GHD aged from 6 months to 17 years old, inclusive.

Read the detailed description

The purpose of this Phase 3 study is to evaluate the safety and efficacy of once-weekly GenSci004 over 108 weeks in children with GHD aged from 6 months to 17 years old, inclusive.

03

Conditions studied

  • GHD

Browse trials for

Keywords

  • GHD
  • growth hormone deficiency
04

Who can participate

Ages eligible
6 Months to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Investigator-determined diagnosis of GHD prior to the historical initiation of daily rhGH trerapy
  2. Participant must be 6 months to 17 years old
  3. Tanner stage \<5 at Visit 1
  4. Open epiphyses
  5. Normal fundoscopy at Screening
  6. Written, signed, of the participant's parent(s)/LAR(s) and written assent of the participant

Exclusion criteria

Exclusion Criteria:

  1. History or presence of malignant disease
  2. Children with diabetes mellitus
  3. Major medical conditions and/or presence of to GH treatment
  4. Pregnancy
  5. Participation in any other study of an agent within three months prior to Visit 1
  6. Prior exposure to investigational drug or any other long-acting growth hormone
  7. Any other reason per investigator's discretion
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
180 participants (estimated)

Study arms

  • Experimental
    GenSci004

    Drug: PEG-somatropin

Interventions

06

What researchers measure

Primary outcomes

  1. Adverse Events of once-weekly GenSci004 in children with GHD

    Incidents of adverse events

    Time frame: 108 weeks

Secondary outcomes

  1. Annualized Height Velocity (AHV)

    Measured in centimeter per year (cm/year)

    Time frame: 104 weeks

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2023; primary completion for May 2025, 17 months later.

Of 19 phase 3 interventional studies under Dwarfism, Pituitary, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 30. This study's planned 17 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 9, 2023
First posted
Sep 6, 2023
StartEst.
Dec 1, 2023
Primary completionEst.
May 1, 2025
CompletionEst.
Sep 1, 2025
Last update
Sep 11, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 11, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06024967
Responsible party
Sponsor
First posted
Sep 6, 2023
Start date
Dec 1, 2023 (estimated)
Primary completion
May 1, 2025 (estimated)
Completion
Sep 1, 2025 (estimated)
Last update
Sep 11, 2023

Study contacts

Duan Peng
Contact
info@gensci-china.com
+86-431-85195060
Lawrence Silverman, MD
study chair · Morristown Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Human Growth Hormone

Start the discussion